Literature DB >> 28780743

High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases.

Mengxi Ge1, Yingjie Zhuang2, Xinli Zhou1, Ruofan Huang1, Xiaohua Liang3, Qiong Zhan1.   

Abstract

Lung cancer is the leading cause of cancer death in men and women worldwide. Brain metastasis (BMs) of non-small cell lung cancer (NSCLC) is the most important cause of death. This study aimed to explore the association of epidermal growth factor receptor (EGFR) mutations and BMs in NSCLC. We analyzed 50 NSCLC patients with BMs and 50 match-paired NSCLC patients with no brain metastases (NBMs). The EGFR mutation status of primary lesions was detected using the amplification refractory mutation system polymerase chain reaction. The BMs patients had a higher frequency of EGFR mutations than the NBMs patients (52.0 vs. 22.0% respectively, P < 0.001), in both adenocarcinoma (60.5 vs. 30.6%, P = 0.003) and squamous carcinoma (37.5 vs. 0%, P = 0.04). The incidence of BMs in patients with EGFR mutations was higher than in patients with wild-type EGFR (70.3 vs. 38.1%, P = 002). NSCLC patients with BMs had a higher incidence of EGFR mutations and those with mutant EGFR had a higher frequency of BMs. EGFR mutations may promote brain metastasis growth of NSCLC.

Entities:  

Keywords:  Brain metastases; Epidermal growth factor receptor; Non-small cell lung cancer; Tyrosine kinase inhibitor

Mesh:

Substances:

Year:  2017        PMID: 28780743     DOI: 10.1007/s11060-017-2590-x

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  23 in total

1.  EGFR mutation and brain metastasis in pulmonary adenocarcinomas.

Authors:  Dong-Yeop Shin; Im Il Na; Cheol Hyeon Kim; Sunhoo Park; HeeJong Baek; Sung Hyun Yang
Journal:  J Thorac Oncol       Date:  2014-02       Impact factor: 15.609

2.  Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST study.

Authors:  Yisheng Huang; Li Zhang; Yuankai Shi; Shenglin Ma; Meilin Liao; Chunxue Bai; Qingyuan Zhang; Changli Wang; Feng Luo; Shiying Yu; Shukui Qin; Xiuyi Zhi; Caicun Zhou
Journal:  Jpn J Clin Oncol       Date:  2015-04-07       Impact factor: 3.019

3.  Frequency of and variables associated with the EGFR mutation and its subtypes.

Authors:  Tomoaki Tanaka; Masaru Matsuoka; Akihisa Sutani; Akihiko Gemma; Makoto Maemondo; Akira Inoue; Shoji Okinaga; Makoto Nagashima; Satoshi Oizumi; Kazutsugu Uematsu; Yoshiaki Nagai; Gaku Moriyama; Hitoshi Miyazawa; Kenji Ikebuchi; Satoshi Morita; Kunihiko Kobayashi; Koichi Hagiwara
Journal:  Int J Cancer       Date:  2010-02-01       Impact factor: 7.396

4.  Screening for epidermal growth factor receptor mutations in lung cancer.

Authors:  Rafael Rosell; Teresa Moran; Cristina Queralt; Rut Porta; Felipe Cardenal; Carlos Camps; Margarita Majem; Guillermo Lopez-Vivanco; Dolores Isla; Mariano Provencio; Amelia Insa; Bartomeu Massuti; Jose Luis Gonzalez-Larriba; Luis Paz-Ares; Isabel Bover; Rosario Garcia-Campelo; Miguel Angel Moreno; Silvia Catot; Christian Rolfo; Noemi Reguart; Ramon Palmero; José Miguel Sánchez; Roman Bastus; Clara Mayo; Jordi Bertran-Alamillo; Miguel Angel Molina; Jose Javier Sanchez; Miquel Taron
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

5.  EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases.

Authors:  Dongdong Luo; Xin Ye; Zheng Hu; Kaiwen Peng; Ye Song; Xiaolu Yin; Guanshan Zhu; Qunsheng Ji; Yuping Peng
Journal:  Tumour Biol       Date:  2013-11-07

6.  Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites.

Authors:  Carlos Gomez-Roca; Christophe M Raynaud; Frederique Penault-Llorca; Olaf Mercier; Frederic Commo; Luc Morat; Laure Sabatier; Philipe Dartevelle; Estelle Taranchon; Benjamin Besse; Pierre Validire; Antoine Italiano; Jean-Charles Soria
Journal:  J Thorac Oncol       Date:  2009-10       Impact factor: 15.609

7.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

Review 8.  Current therapeutic approaches in patients with brain metastases.

Authors:  Kevin H Peacock; Glenn J Lesser
Journal:  Curr Treat Options Oncol       Date:  2006-11

9.  Stereotactic radiosurgery for brain metastasis in non-small cell lung cancer.

Authors:  Yong Kyun Won; Ja Young Lee; Young Nam Kang; Ji Sun Jang; Jin-Hyoung Kang; So-Lyoung Jung; Soo Yoon Sung; In Young Jo; Hee Hyun Park; Dong-Soo Lee; Ji Hyun Chang; Yun Hee Lee; Yeon-Sil Kim
Journal:  Radiat Oncol J       Date:  2015-09-30

10.  Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.

Authors:  Qiuyi Zhang; Xuchao Zhang; Honghong Yan; Benyuan Jiang; Chongrui Xu; Jinji Yang; Zhihong Chen; Jian Su; Yi-Long Wu; Qing Zhou
Journal:  Thorac Cancer       Date:  2016-09-01       Impact factor: 3.500

View more
  23 in total

1.  Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary?

Authors:  Alessandro Leonetti; Francesco Facchinetti; Marcello Tiseo
Journal:  Ann Transl Med       Date:  2018-12

Review 2.  Brain metastases in oncogene-driven non-small cell lung cancer.

Authors:  Makoto Nishino; Kenzo Soejima; Tetsuya Mitsudomi
Journal:  Transl Lung Cancer Res       Date:  2019-11

Review 3.  Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.

Authors:  Natalie M Andrews Wright; Glenwood D Goss
Journal:  Transl Lung Cancer Res       Date:  2019-11

Review 4.  Leptomeningeal Metastases: New Opportunities in the Modern Era.

Authors:  Jessica A Wilcox; Min Jun Li; Adrienne A Boire
Journal:  Neurotherapeutics       Date:  2022-07-05       Impact factor: 7.620

5.  Targeting S100A9-ALDH1A1-Retinoic Acid Signaling to Suppress Brain Relapse in EGFR-Mutant Lung Cancer.

Authors:  Seoyoung Han; Yifan Tai; Wanchao Ma; Courtney Coker; Anup Kumar Biswas; S Aidan Quinn; Ahmad Rushdi Shakri; Timothy James Zhong; Hanna Scholze; Galina G Lagos; Angeliki Mela; Katia Manova-Todorova; Elisa de Stanchina; Adolfo A Ferrando; Cathy Mendelsohn; Peter Canoll; Helena A Yu; Paul K Paik; Anjali Saqi; Catherine A Shu; Mark G Kris; Joan Massague; Swarnali Acharyya
Journal:  Cancer Discov       Date:  2022-04-01       Impact factor: 38.272

Review 6.  Immune Microenvironment of Brain Metastases-Are Microglia and Other Brain Macrophages Little Helpers?

Authors:  Hua You; Szymon Baluszek; Bozena Kaminska
Journal:  Front Immunol       Date:  2019-08-20       Impact factor: 7.561

7.  Distribution Of Brain Metastasis From Lung Cancer.

Authors:  Guangyu Wang; Jiying Xu; Yana Qi; Jianjun Xiu; Ranran Li; Mingyong Han
Journal:  Cancer Manag Res       Date:  2019-11-01       Impact factor: 3.989

Review 8.  Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer.

Authors:  William J Kelly; Neil J Shah; Deepa S Subramaniam
Journal:  Front Oncol       Date:  2018-07-03       Impact factor: 6.244

9.  Characterization of genetic alterations in brain metastases from non-small cell lung cancer.

Authors:  Li Liao; Xiaoyu Ji; Mengxi Ge; Qiong Zhan; Ruofan Huang; Xiaohua Liang; Xinli Zhou
Journal:  FEBS Open Bio       Date:  2018-08-30       Impact factor: 2.693

10.  Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases.

Authors:  Iris M Goldstein; Laila C Roisman; Shoshana Keren-Rosenberg; Julia Dudnik; Hovav Nechushtan; Ilan Shelef; Vered Fuchs; Waleed Kian; Nir Peled
Journal:  Neurooncol Adv       Date:  2020-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.